Clinical Trial Details


Research Study Summary

Advanced Stage Non-small Cell Lung Cancer


Study to evaluate the long-term safety and efficacy of Darbepoetin Alfa in anemic subjects with Advanced Stage Non-small Cell Lung Cancer receiving multi-cycle chemotherapy.

Patient Inclusion Criteria:

  • Subjects with metastatic (stage IV) Non-small Cell Lung cancer, receiving or about receive first line cyclic chemotherapy, life expectancy >6 months, 18 years and older

Patient Exclusion Criteria:

  • Subjects with a history of brain metastasis, known primary benign or malignant hematologic disorder which can cause anemia, history of or current, active cancer (other than non-small lung), uncontrolled angina, uncontrolled heart failure or uncontrolled chronic cardiac arrhythmia, subject with history of a seizure disorder.

To Learn more

CW ID: 163093
Date Last Changed: July 24, 2013

Clinical Trial Snapshot

Both Male and Female
18 and up
Overall Status
Facility Type


Dr. Tom Davis, Director of Business Development
Legacy Pharma Research
601 N. 5th St.
Bismarck, ND 58501
Phone: 701-751-1128
Fax: 701-751-1131

View Map

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.